Capgemini SE : Good timing to go long again
BUY
Repli_rebond
Target price hit
Entry price | Target | Stop-loss | Potential |
---|
€155.4 |
€176 |
€145 |
+13.26% |
---|
The support at 155.4 EUR, which is currently being tested, should allow Capgemini SE shares to move back to the upside.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses● The company appears highly valued given the size of its balance sheet.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.